Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Basit Öğe Kaydı
dc.authoridBondarenko, Igor/0000-0002-7071-2471;
dc.authorwosidBondarenko, Igor/U-5156-2017
dc.authorwosidZavizion, Viktor/C-2550-2019
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.contributor.authorBondarenko, I.
dc.contributor.authorSezer, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorGumus, M.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.date.accessioned2024-06-12T11:13:23Z
dc.date.available2024-06-12T11:13:23Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS951en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10en_US
dc.identifier.startpageS951en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23528
dc.identifier.volume16en_US
dc.identifier.wosWOS:000709606500217en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRandomised Controlled Trialsen_US
dc.subjectPhase II And III Clinical Trialsen_US
dc.subjectImmune Checkpoint Inhibitorsen_US
dc.titleClinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu